Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective.
Keith W PratzXinglei ChaiJipan XieLei YinXiaoyu NieMelissa MontezErica IantuonoLisa DownsEsprit MaPublished in: PharmacoEconomics (2022)
ClinicalTrials.gov, NCT02993523. Date of registration: 15 December 2016.